NCT05854550View on ClinicalTrials.gov

First in Human Study to Assess an Implant to Treat Severe Emphysema

NAActive, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

October 8, 2024

Study Completion Date

June 1, 2026

Conditions
Emphysema or COPD
Interventions
DEVICE

Apreo Implant Group

One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.

Trial Locations (2)

2109

Macquarie University Hospital, Macquarie

3050

Royal Melbourne Hospital, Parkville

Sponsors

Lead Sponsor

Apreo Health, Inc.
All Listed Sponsors
lead

Apreo Health, Inc.

INDUSTRY

NCT05854550 - First in Human Study to Assess an Implant to Treat Severe Emphysema | Biotech Hunter | Biotech Hunter